Hemodynamic monitoring, the measurement of a patient’s blood circulation and cardiac function, enables clinicians to evaluate whether a patient is receiving enough oxygen to their organs and tissues.
The Irvine, Calif.-based company’s blood monitoring device is wireless and incorporates visual clinical support screens and a touchscreen. The HemoSphere monitor is compatible with the company’s Swan-Ganz pulmonary artery catheter and Oximetry catheters, according to Edwards.
“The HemoSphere advanced monitor enables simplified visual clinical support, which is particularly important in the care of our most complex, critically ill patients,” Dr. Davinder Ramsingh from the Loma Linda University Medical Center said in prepared remarks. “Clinicians can choose the clinical support screens that best suit their needs and monitor the pressures and blood flow of the right heart as conditions change, informing potentially life-saving decisions on behalf of their patients.”
“The HemoSphere advanced monitor builds on Edwards’ more than 50 years of experience in providing clinicians with technology and education to help improve patient care and lays the foundation for future advancements in hemodynamic monitoring,” Edwards’ corporate VP of critical care, Catherine Szyman, added.
In January, the HemoSphere advanced monitor won CE Mark clearance in the European Union. It is also approved for commercial use in Japan, Australia and New Zealand.
EW shares were trading at $95.98 in morning activity, up 1.3%.